Key facts
- Xsensio’s last known valuation is $22.6M (Nov 2025).
- It has raised $13.4M; the latest was Later Stage VC ($7.0M) in Mar 2026.
- Notable investors include European Innovation Council, WI Harper Group.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Xsensio
- ·The full record, as it builds
Funding rounds
No funding rounds for Xsensio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xsensio
Developer of wearable biochemical sensing technology designed for real-time patient monitoring and early detection of clinical deterioration. The company offers Lab-on-Skin biochemical sensing, continuous tracking of inflammation and other critical biomarkers on the skin surface, and proprietary intellectual property and clinical collaborations, enabling healthcare providers in intensive care, oncology, post-surgical recovery, and home-care settings to obtain earlier, more actionable diagnostic data that improves decision-making and health outcomes.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2014
- Employees
- 18
- Website
- xsensio.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Xsensio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xsensio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xsensio in its N-PORT filings yet. We sweep new filings monthly.